Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD0120 vs Standard Regimens in Relapsed Refractory Multiple Myeloma
NCT07391657Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- Feb 2026
- Primary completion
- Jun 2028
- Modality
- CAR-T Cells
- Countries
- 15
01
Overview
A Phase 3 trial of GC012 in multiple myeloma (MM), sponsored by AstraZeneca. Started Feb 2026; status: recruiting.
02
Drugs
GC012
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07391657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07391657.